前列地尔和胰激肽原酶在早期糖尿病肾病患者治疗中的运用价值分析

Analysis of the Application Value of Alprostadil and Kallikrein in the Treatment of Patients with Early Diabetic Nephropathy

目的分析研究前列地尔和胰激肽原酶在早期糖尿病肾病患者治疗中的运用价值。方法选取2017年1月—2021年1月北京市房山区燕化医院接收的100例早期糖尿病肾病患者为研究对象,结合此间早期糖尿病肾病患者应用治疗方法的差异,将其分别纳入对照组和观察组,各50例,依次实施常规治疗及前列地尔和胰激肽原酶治疗,比较在不同干预措施应用下的治疗效果,包括肾功能指标、血糖水平、不良反应发生率、炎性因子水平、生活质量。结果治疗前,两组肾功能指标、血糖水平、炎性因子水平对比差异无统计学意义(P>0.05);治疗后,观察组优于对照组,差异有统计学意义(P<0.05)。对照组不良反应发生率(10.00%)高于观察组(2.00%),但两组数据对比差异无统计学意义(χ^(2)=1.595,P=0.206)。结论在早期糖尿病肾病患者治疗期间,通过予以前列地尔和胰激肽原酶联合治疗方法,改善临床症状的同时有助于改善患者的肾功能,且血糖处于稳定状态,患者的炎性水平有所改善,生活质量随之升高,很大程度上提高了治疗水平。

Objective To analyze the application value of alprostadil and kallikrein in the treatment of patients with early diabetic nephropathy.Methods A total of 100 patients with early diabetic nephropathy received by Beijing Yanhua Hospital from January 2017 to January 2021 were selected as the research objects.Combined with the differ⁃ences in the treatment methods of patients with early diabetic nephropathy,they were included in the control group and the observation group,with 50 cases in each group.Routine therapy,alprostadil and kallikrein therapy were per⁃formed in sequence,and the therapeutic effects,including renal function indexes,blood glucose levels,incidence of adverse reactions,inflammatory factor levels,and quality of life were compared under the application of different in⁃tervention measures.Results Before treatment,there was no statistically significant difference in renal function in⁃dex,blood glucose level,and inflammatory factor level between the two groups(P>0.05);after treatment,the observa⁃tion group was better than the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the control group(10.00%)was higher than that in the observation group(2.00%),but there was no statistically significant difference between the two groups(χ^(2)=1.595,P=0.206).Conclusion During the treat⁃ment of patients with early diabetic nephropathy,the combined therapy of alprostadil and kallikrein can improve the clinical symptoms and improve the renal function of the patients.And blood glucose is in a stable state,the inflamma⁃tory level of patients has improved,and the quality of life has increased,which has greatly improved the level of treat⁃ment.It is worthy of clinical application and promotion.